Growth Metrics

Pacific Biosciences Of California (PACB) Cash from Operations (2016 - 2026)

Pacific Biosciences Of California has reported Cash from Operations over the past 16 years, most recently at 19069000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 37.78% year-over-year to 19069000.0; the TTM value through Dec 2025 reached 111209000.0, up 46.03%, while the annual FY2025 figure was 111209000.0, 46.03% up from the prior year.
  • Cash from Operations for Q4 2025 was 19069000.0 at Pacific Biosciences Of California, down from 18707000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 15712000.0 in Q2 2021 and troughed at 94691000.0 in Q1 2023.
  • A 5-year average of 47903947.37 and a median of 45463000.0 in 2024 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: plummeted 285.46% in 2022 and later skyrocketed 58.85% in 2025.
  • Year by year, Cash from Operations stood at 31708000.0 in 2021, then plummeted by 91.01% to 60566000.0 in 2022, then rose by 4.96% to 57560000.0 in 2023, then soared by 46.75% to 30650000.0 in 2024, then soared by 37.78% to 19069000.0 in 2025.
  • Business Quant data shows Cash from Operations for PACB at 19069000.0 in Q4 2025, 18707000.0 in Q3 2025, and 29377000.0 in Q2 2025.